Genomenon, Inc., a leading provider of genomic intelligence solutions, has announced a strategic partnership with Mirum Pharmaceuticals, Inc. to improve the awareness and diagnosis of Cerebrotendinous ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to ...

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research, and Exact Sciences, a leading provider of cancer screening and diagnostic tests, today ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

This year’s World Cancer Day theme, ‘United by Unique,’ emphasizes a people-centred approach to cancer care, encouraging us ...

North America in vitro diagnostics (IVD) market is projected to grow by 5.6% annually in the forecast period and reach $ 54,000.3 million by 2031. The North America In Vitro Diagn ...

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

Earlier today, Munich Re published the latest chapter in its Life Science Report series, delving into ‘Improving Cancer ...